Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 20 of 46 for “"Exenatide"”.
-
Targeting postprandial hyperglycaemia with exenatide in young people with cystic fibrosis
… this group by use of the GLP-1 receptor agonist, exenatide. The work extends previous studies by colleagues relating to gastric emptying, the incretin effect, and postprandial glycaemia in paediatric populations with CF and type 1 diabetes (T1D), by evaluating a treatment approach that addresses …
-
Exenatide as chronopharmacotherapy for T2DM associated complications: targeting nondipping blood pressure and sleep insufficiency
… BP in db/db mice, the short-acting GLP-1 RA, exenatide, was intraperitoneally injected at the onset of the light (zeitgeber time, [ZT] 0) or dark (ZT12) phase in male diabetic db/db mice and nondiabetic controls (db/+). BP and food intake were simultaneously monitored using radiotelemetry and …
-
Effect of the glucagon-like peptide-1 analogue exenatide extended-release in cats with newly diagnosed diabetes mellitus
Hintergrund: Exenatide extended-release ist ein Glukagon-ähnliches Peptid-1 Analogon, welches in der Humanmedizin bei Typ-2 Diabetes mellitus eingesetzt wird. Es erhöht die Insulinsekretion, inhibiert die Glukagonsekretion und erhöht das Sättigungsgefühl. In Untersuchungen an gesunden Katzen zeigte …
-
Physiology and pharmacology of diabetes therapies in the cat: insulin detemir, insulin glargine, exenatide and the incretin effect
… study the pharmacodynamics of the GLP-1 mimetic, exenatide. An exenatide-specific ELISA was used for evaluation of exenatide pharmacokinetics. Finally, we studied the incretin effect in cats and compared the effect of glucose, lipids or amino acids on secretion of the incretin hormones …
-
Η επίδραση της παρστατίνης 1-26 στη μυοκαρδιακή βλάβη από ισχαιμία και επαναιμάτωση: μελέτη σε πειραματικό μοντέλο κονίκλων
Exenatide and ciclosporin have been shown to partially protect myocardial tissue damage after reperfusion. In the present thesis it is proposed to combine more than one cardioprotective agent, targeting more pharmacological targets, where it could provide more effective myocardial protection and …
-
Physiological, Morphological and molecular biological studies of the effect of Glucagon-like peptide-1 and exenatide in the diabetic rat pancreas
… peptide-1 (GLP-1) and its synthetic agonist, exenatide on the diabetic rat pancreas compared to healthy, agematched controls. These incretins exert their beneficial effects by repairing the pancreatic islets. Thus, increasing pancreatic beta (β) cell mass and in turn it will help to synthesize …
-
Ελάττωση του τραύματος ισχαιμίας-επαναιμάτωσης του μυοκαρδίου σε απομονωθείσα καρδιά επίμυων, με τη βοήθεια φαρμακευτικών παραγόντων
… cardiovascular pathologies, levosimendan and exenatide in various concentrations, as well as of the coadministration of those agents in an isolated rat heart model of ischemia/reperfusion injury.Methods: The non-working ‘Langendorff’ isolated heart perfusion model was used in the study. This …
-
Mελέτη μεταγευματικής λιπαιμίας σε άτομα με σακχαρώδη διαβήτη τύπου 2: σύγκριση θεραπείας με λιραγλουτίδη έναντι εξενατίδης
… and in particular postprandial dyslipidaemia. Exenatide and liraglutide are two GLP-1 receptor agonists which are currently available as subcutaneously administered treatment for T2DM but their chronic effects on postprandial lipaemia have not been well investigated.The aim of this study was to …
-
A 4-month randomized controlled clinical trial of adjuvant exenatide or pramlintide versus insulin alone in pediatric type 1 diabetes mellitus: Effect on glycemic control
… effects of 16 weeks of treatment with adjuvant Exenatide or Pramlintide versus insulin alone on glycemic control, as measured by glycated hemoglobin (HbA1C) and 1,5-Anhydroglucitol (1,5-AG), or GlycoMark, in pediatric Type 1 Diabetes Mellitus (T1DM). We present here the preliminary results …
-
GLP1R IS A T CELL NEGATIVE COSTIMULATORY MOLECULE
… the treatment with the GLP1R agonist Exenatide significantly prolonged cardiac and islet allograft survival and reduced graft T lymphocytes infiltrate. Interestingly, a strong synergism in mitigating alloimmunity was observed between Exenatide and Rapamycin. Mechanistically, mitogen …
-
ENERGY EXPENDITURE, GLUCOSE METABOLISM AND BODY COMPOSITION IN BABOONS AT BASELINE AND AFTER A PARTIAL PANCREATECTOMY AND A 13 WEEKS OF CONTINUOUS INFUSION OF EXENATIDE
… of a medication for the treatment of T2DM (Exenatide) in a non-human primate, in a model with impaired β-cell function, reporting a insulin sensitizing effect in the Exenatide-treated group, an increase insulin sensitivity and β-cells function and decrease in total body weight. This type of …
-
Strategies for targeted immunomodulation
… of therapeutics. Conjugates formulated with Exenatide and Glibenclamide targeting ligands with short synthetic linkers were highly internalized into β cells. Bivalent Glibenclamide conjugates exhibited increased potency for β cell labeling and could be used to selectively deliver β cell …
-
Polyglycerol for Half-Life Extension and Increased Stability of Biopharmaceuticals
… of the propargyl-modified diabetes therapeutic exenatide. LPG-N3 of 10, 20 and 40 kDa was employed to synthesize conjugates by Cu-catalyzed click-chemistry. PEG-conjugates of similar molecular weights again served as reference. The secondary structure of exenatide was not altered by polymer …
-
Human physiology of intra-cranial pressure and the biological role of GLP-1 agonists
Pre-clinical data demonstrates the ability of Exenatide, a GLP-1R agonist, to reduce CSF secretion and intracranial pressure (ICP) in an in vivo model. Existing GLP-1R agonists are widely used to treat obesity and diabetes (but do not cause hypoglycaemia). In the IIH Pressure trial 16 female …
-
Micelles For Oral Delivery Of Biomacromolecules
… was further extended for oral delivery of exenatide, a glucagon-like peptide receptor 1 agonist (GLP-1RA). High pharmacological activity (>40%) was achieved on diabetic mice and minipig models, meanwhile, nausea, a common side effect associated with regular subcutaneous exenatide treatment, …
-
Investigation of cell-based therapies employing microcapsules and microspheres: encapsulation and controlled release
… we encapsulated porcine islets together with exenatide-loaded poly(latic-co-glycolic acid) MSs to enhance islet survival and function as exenatide locally released in the intracapsular environment. The MCs with exenatide-loaded MSs showed improved glucose-stimulated response. The results …
Page 1 of 3